Overview

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Status:
Suspended

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to estimate the therapeutic efficacy of the experimental targeted regimen including the EGFR antibody panitumumab (in combination with pemetrexed and cisplatin) in relation to the standard combination in patients with a KRAS wild-type stage IIIB or IV primary nonsquamous non-small cell lung cancer. It is expected that the progression free survival rate at 6 months is improved by the targeted regimen.

Phase:

Phase 2

Details

Lead Sponsor:

WiSP Wissenschaftlicher Service Pharma GmbH

Collaborators:

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

Treatments:

Antibodies, Monoclonal
Cisplatin
Panitumumab
Pemetrexed